ITGA2 Antibody-Drug Conjugates for Solid Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer, such as surgery, radiotherapy, and chemotherapy, are ineffective in addressing metastasis, relapse, and drug resistance in cancer cells, resulting in low long-term survival rates for patients.
Innovation Solution
Development of an antibody specifically binding to the ITGA2 protein, which is overexpressed in various solid tumors, and its use in forming an antibody-drug conjugate to target and kill ITGA2-positive tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgery, radiotherapy, and chemotherapy are used to treat cancer, then short-term therapeutic effect is achieved, but long-term survival rate remains low due to metastasis, relapse, and drug resistance
Solution Approach 1:
The patent segments the treatment approach by developing multiple antibody variants (FS002-A1, FS002-A5, FS002-A15, etc.) that specifically target different epitopes of the ITGA2 antigen. This segmentation allows for more precise targeting of cancer cells expressing ITGA2, thereby improving long-term therapeutic effectiveness while reducing damage to normal cells.
Solution Approach 2:
The patent applies parameter changes by modifying the antibody structure to optimize binding affinity to ITGA2. The inventors developed humanized antibodies with specific variable region sequences that enhance specificity and affinity for ITGA2-positive tumor cells, thereby improving the reliability of long-term treatment outcomes.
2Adaptability or versatility
If chemotherapy is used to treat metastatic cancer, then it can be used for patients with cancer spread, but strong toxic side effects and drug resistance limit its effectiveness to only 20-30% of patients
Solution Approach 1:
The patent uses the antibody as an intermediary that specifically binds to ITGA2 on the surface of metastatic cancer cells. This intermediary approach delivers the therapeutic effect directly to target cells while sparing normal tissues, thereby improving both the adaptability to metastatic cancer and the reliability of therapeutic effectiveness.
Solution Approach 2:
The patent replaces the non-specific mechanical action of chemotherapy drugs with a biologically specific antibody-antigen recognition system. The humanized antibodies specifically recognize and bind to ITGA2, providing a more precise and effective treatment for metastatic cancer with reduced toxicity.
3Measurement precision
If existing antibodies targeting ITGA2 are used, then they can bind to ITGA2 protein, but they do not have good inhibition effect on tumor cell growth
Solution Approach 1:
The patent optimizes the binding parameters of the antibody by humanizing the variable regions and selecting specific CDR sequences that enhance both affinity for ITGA2 and functional activity. The modified antibodies demonstrate improved tumor cell growth inhibition while maintaining high binding specificity.
Solution Approach 2:
The patent creates composite antibody structures combining humanized variable regions with appropriate constant regions, optimizing both binding precision and biological activity. The composite structure enables the antibody to not only bind ITGA2 with high precision but also effectively inhibit tumor cell growth through immune-mediated mechanisms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody and antibody-drug conjugate demonstrate excellent binding affinity to ITGA2-positive tumor cells, achieving significant killing effects and potentially improving treatment outcomes for patients with solid tumors.
Implementation Method 1
an isolated antibody specifically binding to an ITGA2 protein or an antigen-binding fragment thereof
Data Source
AI summary
The present invention provides a series of antibodies or antigen-binding fragments thereof with high specific binding ability to tumor cells expressing the ITGA2 protein. The antibody or the antigen-binding fragment thereof according to the present invention may achieve excellent killing effect on tumor cells after being conjugated with a drug to form an antibody-drug conjugate.